A Phase 2, Open-Label Randomized Trial Evaluating the Efficacy and Safety of Two Dosages of Once Daily Oral CA-170 in Patients with Selected Relapsed Advanced Tumors (ASIAD)
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2019
At a glance
- Drugs CA 170 (Primary)
- Indications Head and neck cancer; Hodgkin's disease; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Aurigene Discovery Technologies
- 07 Nov 2018 According to a Curis media release, data from this trial will be presented at the 33rd Society for Immunotherapy of Cancer Annual Meeting
- 02 Aug 2018 According to a Curis media release, Aurigene is continuing patient enrolment at select sites in India, additional updates are expected in 2H 2018.
- 08 Mar 2018 Status changed from planning to recruiting, according to a Curis media release.